Clinical trials: Buprenorphine
Cigarette Smoking Among Patients Currently Receiving Methadone or Buprenorphine Treatment for Opioid Dependence
Incentive-based Smoking Cessation for Methadone Patients
The prevalence of cigarette smoking among patients receiving opioid agonist treatment, such as methadone or buprenorphine maintenance, is more than three-fold that of the general population and is associated with increased…
- Trial name
- NCT00718835
- Testing
- incentive-based contingency management
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- University of Vermont Medical Center
Opioid Use Disorder, Peer Recovery Supporters
Peer Recovery Support for Opioid Use Disorder Treatment Retention
The goal of this clinical trial is to learn whether adding peer recovery support services to standard opioid use disorder (OUD) treatment in primary care helps patients stay in treatment longer.
- Conditions
- Opioid Use Disorder, Peer Recovery Supporters, Peer Recovery Coaching, Primary Care
- Trial name
- NCT07620171
- Testing
- Peer Support
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Opioid-Related Disorders
Comparison of Buprenorphine and Methadone - 3
The purpose of this study is to compare agonist and antagonist profile associated with buprenorphine vs. methadone during opiate withdrawal.
- Trial name
- NCT00000334
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Hepatitis C, Chronic
Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)
This randomized, single-center, controlled study is designed to evaluate the safety, tolerability, and efficacy of treatment with Peg-Intron with Rebetol in methadone or buprenorphine maintenance patients with hepatitis C.
- Trial name
- NCT00279565
- Testing
- buprenorphine, methadone, pegylated interferon alfa-2b plus ribavirin
- Volunteers
- 128 people
- Sponsor
- Indivior Inc.
Opioid-Related Disorders
Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13
The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with pro-social activities.
- Trial name
- NCT00000231
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid Use Disorder, Fentanyl
Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation
The goal of this pragmatic randomized controlled trial is to compare treatment outcomes of two strategies for initiating buprenorphine treatment (low-dose initiation and direct-to-inject) in adults with opioid use disorder (OUD)…
- Trial name
- COPILOT (NCT07469501)
- Testing
- Injectable buprenorphine, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Opioid-Related Disorders
Multicenter Clinical Trial of Buprenorphine - 3
The purpose of this study is to test the efficacy and safety of buprenorphine.
- Trial name
- NCT00000207
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- University of California, Los Angeles
Chronic Pain, Opioid Addiction
Yoga for Pain and Opioid Dependence
This study is designed to develop an effective adjunctive treatment using yoga for chronic pain and opioid dependence.
- Trial name
- Yoga (NCT01590251)
- Testing
- Yoga, Educational Counseling
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Yale University
Opioid-Related Disorders, Substance-Related Disorders
Trial of Buprenorphine/Naloxone for Opiate Dependence - 2
The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate dependence treatment.
- Trial name
- NCT00000353
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid-use Disorder
Buprenorphine Treatment Engagement and Overdose Prevention
Office-based buprenorphine could be expanded to treat many of the opioid users who are not in treatment and who are at great risk for opioid overdose, but effective approaches are needed to help individuals with opioid use…
- Trial name
- NCT03677986
- Testing
- Video DOT+
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Johns Hopkins University
Opioid-use Disorder
Treatment for Opiate Addiction: Prognostic fActors of Responsiveness to Maintenance Treatment
A global and integrative treatment of opioid-use disorders (OUD) with opiate maintenance therapy (OMT) and psychosocial interventions is recommended by all current guidelines.
- Trial name
- TOPAZE (NCT03729388)
- Testing
- Prognosis factor associated with good outcome.
- Where
- 2 sites in France
- Volunteers
- 29 people
- Sponsor
- Nantes University Hospital
Opioid-use Disorder
Feasibility of Pediatric Emergency Department-Initiated Treatment for Adolescents With Opioid Use Disorder
ED-initiated buprenorphine with brief intervention and facilitated referral to treatment has been shown to be highly successful in increasing treatment engagement rates and reducing opioid use among adults.
- Trial name
- PEDsTREATOUD (NCT04737603)
- Testing
- ED-Initiated treatment with buprenorphine / naloxone
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, Davis
Neonatal Abstinence Syndrome
Fetal and Infant Effects of Maternal Buprenorphine Treatment
This research will track the longitudinal neurobehavioral development of the buprenorphine-exposed fetus across gestation through 1 month of age in an effort to determine the safety of this medication for use during gestation…
- Trial name
- NCT01561079
- Testing
- Buprenorphine
- Where
- 2 sites in United States
- Volunteers
- 127 people
- Sponsor
- Johns Hopkins University
Neonatal Abstinence Syndrome
Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome
The opioid neonatal abstinence syndrome (NAS) is a condition of withdrawal symptoms after utero exposure to opioids. In an open label Phase 1 trial sublingual buprenorphine was associated with a ~30% reduction length of treatment…
- Trial name
- NCT01452789
- Testing
- sublingual buprenorphine, oral morphine
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Thomas Jefferson University
Pain
Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film
The primary aim of this study is to determine if chronic pain subjects on around-the-clock opioids who are receiving 100 to 220 mg oral morphine sulfate equivalent (MSE) can be safely transitioned on to buprenorphine…
- Trial name
- NCT01871285
- Testing
- Buprenorphine, Oxycodone, Morphine sulfate
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- BioDelivery Sciences International